GenVec Stock Price, News & Analysis (NASDAQ:GNVC)

Previous Close$7.21
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio-1.96
Dividend YieldN/A
BetaN/A

About GenVec (NASDAQ:GNVC)

GenVec logoGenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Receive GNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for GNVC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GNVC
CUSIPN/A
Phone+1-240-6320740

Debt

Debt-to-Equity RatioN/A
Current Ratio2.10%
Quick Ratio2.10%

Price-To-Earnings

Trailing P/E Ratio-1.95994550408719
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($3.67)
Net IncomeN/A
Net Margins-3,748.25%
Return on Equity-648.22%
Return on Assets-271.77%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

GenVec (NASDAQ:GNVC) Frequently Asked Questions

What is GenVec's stock symbol?

GenVec trades on the NASDAQ under the ticker symbol "GNVC."

When did GenVec's stock split? How did GenVec's stock split work?

GenVec's stock reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.

How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) issued its quarterly earnings data on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.07 million. GenVec had a negative net margin of 3,748.25% and a negative return on equity of 648.22%. View GenVec's Earnings History.

Who are some of GenVec's key competitors?

Who are GenVec's key executives?

GenVec's management team includes the folowing people:

  • Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
  • Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
  • William N. Kelley M.D., Independent Director
  • Stefan D. Loren Ph.D., Independent Director
  • Quinterol J. Mallette M.D., Independent Director
  • Michael S. Richman, Independent Director
  • Marc R. Schneebaum, Independent Director

How do I buy GenVec stock?

Shares of GenVec can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact GenVec?

GenVec's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.


MarketBeat Community Rating for GenVec (GNVC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GenVec (NASDAQ:GNVC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AHoldHoldHold
Consensus Rating Score: N/A2.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$7.00$7.00$7.00
Price Target Upside: N/A6.54% upside6.54% upside6.54% upside

GenVec (NASDAQ:GNVC) Consensus Price Target History

Price Target History for GenVec (NASDAQ:GNVC)

GenVec (NASDAQ:GNVC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2017HC WainwrightDowngradeHold$7.00N/AView Rating Details
1/25/2017Rodman & RenshawDowngradeBuy -> Neutral$15.00 -> $7.00N/AView Rating Details
7/26/2016Roth CapitalReiterated RatingBuy$80.00 -> $20.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

GenVec (NASDAQ:GNVC) Earnings History and Estimates Chart

Earnings by Quarter for GenVec (NASDAQ:GNVC)

GenVec (NASDAQ GNVC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($1.88)$0.11 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.67)$0.02 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.08)($0.05)$0.07 million$0.17 millionViewN/AView Earnings Details
8/5/2016Q116($0.10)($0.06)$0.12 million$0.03 millionViewN/AView Earnings Details
5/12/2016Q1 2016($0.09)($0.11)$0.18 million$0.29 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.10)$0.21 million$0.16 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.11)($0.09)$0.15 million$0.19 millionViewN/AView Earnings Details
8/7/2015Q215($0.10)($0.11)$0.38 million$0.13 millionViewN/AView Earnings Details
5/8/2015Q115($0.06)($0.09)$0.91 million$0.41 millionViewN/AView Earnings Details
3/24/2015Q414$0.08$0.11$3.33 million$3.50 millionViewListenView Earnings Details
11/12/2014Q314($0.09)($0.10)$1.00 million$0.25 millionViewN/AView Earnings Details
8/12/2014Q214($0.15)($0.10)$0.13 millionViewN/AView Earnings Details
5/12/2014Q114$0.04($0.07)$2.00 million$2.10 millionViewN/AView Earnings Details
3/28/2014Q413($0.16)($0.07)$1.52 million$0.15 millionViewListenView Earnings Details
11/12/2013Q313($0.23)$2.10 million$1.60 millionViewN/AView Earnings Details
8/13/2013Q2 2013($2.40)$0.75 millionViewN/AView Earnings Details
5/10/2013Q1 2013($2.40)$1.21 millionViewN/AView Earnings Details
3/22/2013Q4 2012($2.70)($2.40)ViewN/AView Earnings Details
11/9/2012Q312($0.32)($0.30)$2.90 million$2.13 millionViewN/AView Earnings Details
8/9/2012Q2 2012($1.40)($2.83)ViewN/AView Earnings Details
5/10/2012Q1 2012($1.30)($2.47)ViewN/AView Earnings Details
3/15/2012Q4 2011($1.40)($1.94)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.70)($1.10)ViewN/AView Earnings Details
8/9/2011Q2 2011($1.90)($0.96)ViewN/AView Earnings Details
5/9/2011Q1 2011($1.50)($1.72)ViewN/AView Earnings Details
3/10/2011Q4 2010($2.00)($0.80)ViewN/AView Earnings Details
11/8/2010Q3 2010($3.00)($2.00)ViewN/AView Earnings Details
8/5/2010Q2 2010($3.00)($3.30)ViewN/AView Earnings Details
5/6/2010Q1 2010($3.00)($3.90)ViewN/AView Earnings Details
3/11/2010Q4 2009($3.00)($4.10)ViewN/AView Earnings Details
11/5/2009Q3 2009($4.00)($3.50)ViewN/AView Earnings Details
8/6/2009Q2 2009($7.00)($5.20)ViewN/AView Earnings Details
5/7/2009Q1 2009($6.00)($6.40)ViewN/AView Earnings Details
3/12/2009Q4 2008($8.00)($7.30)ViewN/AView Earnings Details
11/6/2008Q3 2008($7.00)($7.70)ViewN/AView Earnings Details
8/7/2008Q2 2008($7.00)($8.30)ViewN/AView Earnings Details
5/8/2008Q1 2008($6.00)($8.30)ViewN/AView Earnings Details
3/13/2008Q4 2007($6.00)($5.90)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

GenVec (NASDAQ:GNVC) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for GenVec (NASDAQ:GNVC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GenVec (NASDAQ GNVC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 6.22%
Insider Trades by Quarter for GenVec (NASDAQ:GNVC)
Insider Trades by Quarter for GenVec (NASDAQ:GNVC)

GenVec (NASDAQ GNVC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/16/2016Douglas J SwirskyCEOBuy10,000$0.50$5,000.00252,500View SEC Filing  
12/14/2015Douglas J SwirskyCEOBuy5,000$2.00$10,000.00242,500View SEC Filing  
11/16/2015Stefan LorenDirectorBuy4,000$1.93$7,720.005,000View SEC Filing  
8/11/2015Douglas E BroughInsiderBuy4,600$2.34$10,764.00View SEC Filing  
5/27/2014Ecor1 Capital, LlcMajor ShareholderBuy24,140$2.24$54,073.60View SEC Filing  
3/28/2014Ecor1 Capital, LlcMajor ShareholderBuy122,273$2.55$311,796.15View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GenVec (NASDAQ GNVC) News Headlines

Source:
DateHeadline
Analyzing Ligand Pharmaceuticals (LGND) and GenVec (GNVC)Analyzing Ligand Pharmaceuticals (LGND) and GenVec (GNVC)
www.americanbankingnews.com - February 4 at 5:10 PM
GenVec (GNVC) versus The Competition Financial ContrastGenVec (GNVC) versus The Competition Financial Contrast
www.americanbankingnews.com - December 25 at 5:10 AM
Comparing GenVec (GNVC) & Its RivalsComparing GenVec (GNVC) & Its Rivals
www.americanbankingnews.com - December 22 at 11:32 AM
Reviewing GenVec (GNVC) & Its RivalsReviewing GenVec (GNVC) & Its Rivals
www.americanbankingnews.com - December 21 at 7:10 PM
Reviewing GenVec (GNVC) & Its PeersReviewing GenVec (GNVC) & Its Peers
www.americanbankingnews.com - December 19 at 5:26 AM
GenVec (GNVC) and Its Rivals Head-To-Head AnalysisGenVec (GNVC) and Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - December 17 at 3:12 AM
GenVec (GNVC) vs. Its Rivals Financial ReviewGenVec (GNVC) vs. Its Rivals Financial Review
www.americanbankingnews.com - November 27 at 11:24 PM
Aptose Biosciences (APTO) & GenVec (GNVC) Financial SurveyAptose Biosciences (APTO) & GenVec (GNVC) Financial Survey
www.americanbankingnews.com - November 14 at 1:36 PM
GenVec (GNVC) versus CTI BioPharma Corp. (CTIC) Critical ReviewGenVec (GNVC) versus CTI BioPharma Corp. (CTIC) Critical Review
www.americanbankingnews.com - October 24 at 8:50 PM
GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - October 5 at 8:13 AM
Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec AcquisitionIntrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition
finance.yahoo.com - October 5 at 8:13 AM
Reviewing Arena Pharmaceuticals (ARNA) and GenVec (GNVC)Reviewing Arena Pharmaceuticals (ARNA) and GenVec (GNVC)
www.americanbankingnews.com - October 4 at 12:24 AM
Head to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC)Head to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC)
www.americanbankingnews.com - August 30 at 9:12 AM
Intrexon Integrates Leading Adenoviral Gene Delivery Technology with ...Intrexon Integrates Leading Adenoviral Gene Delivery Technology with ...
www.prnewswire.com - June 17 at 10:55 PM
How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion PharmaHow These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma
www.bizjournals.com - April 28 at 10:35 AM
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.
feeds.benzinga.com - April 17 at 9:21 PM
GENVEC INC Files SEC form 10-K, Annual ReportGENVEC INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 6 at 5:07 PM
WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release)WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release)
www.prnewswire.com - February 8 at 11:04 PM
Rodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - StreetInsider.comRodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - StreetInsider.com
www.streetinsider.com - January 26 at 6:57 PM
Intrexon To Buy GenVec For $7 a Share (XON, GNVC)Intrexon To Buy GenVec For $7 a Share (XON, GNVC)
www.investopedia.com - January 25 at 4:51 PM
Intrexon To Buy GenVec In Stock Deal For $7/ShrIntrexon To Buy GenVec In Stock Deal For $7/Shr
www.investopedia.com - January 25 at 4:51 PM
GenVec Inc. (GNVC) Is Up Sharply After Bought By IntrexonGenVec Inc. (GNVC) Is Up Sharply After Bought By Intrexon
www.rttnews.com - January 24 at 6:14 PM
GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of SecuritGENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit
biz.yahoo.com - January 24 at 6:14 PM
East Coast biotech company licenses Washington U technologyEast Coast biotech company licenses Washington U technology
www.bizjournals.com - January 9 at 4:18 PM
GenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. LouisGenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. Louis
us.rd.yahoo.com - January 5 at 6:28 PM
8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting
us.rd.yahoo.com - January 5 at 6:28 PM

SEC Filings

GenVec (NASDAQ:GNVC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GenVec (NASDAQ:GNVC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GenVec (NASDAQ GNVC) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.